2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1072

Enzymatic Lipid Oxidation Contributes to the Maintenance of Self-Tolerance by Regulating Antigen Clearance and Dendritic Cell Function
Abstract Number: 556

Eos Imaging Could Replace Conventional Computed Radiography for Ankylosis Assessment in Axial Spondyloarthritis
Abstract Number: 14

EPAC1 Activation Is Required for NFkB Nuclear Translocation and Osteoclast Differentiation
Abstract Number: 1261

Epicardial Adipose Tissue Is Associated with Cardiometabolic Risk and the Metabolic Syndrome in Patients with Rheumatoid Arthritis
Abstract Number: 929

Epidemiology of the US National Burden of Pediatric Lupus Hospitalization From 2000-2009
Abstract Number: 313

Epigenetic Changes in Fibrosis and Myocyte Repair Genes May Contribute to Pathogenesis in Monozygotic Twins Discordant for Cardiac Manifestations of Neonatal Lupus
Abstract Number: 427

Epigenetic Features As Predictive Markers of Responsiveness to Epitope-Specific Therapy in Rheumatoid Arthritis
Abstract Number: 2284

Epigenetic Profiling in Monozygotic Twins Discordant for Systemic Lupus Erythematosus Reveals Prominent Hypomethylation of Interferon-Inducible Genes
Abstract Number: 2594

Epigenetic Signature of the Response to Anti-TNF in Juvenile Idiopathic Arthritis
Abstract Number: 419

Epigenome Analysis of Rheumatoid Arthritis Synovial Fibroblasts Revealed TBX-5 As a Novel Transcription Factor in Chemokine Regulation
Abstract Number: 1000

Epistatic Interaction Between BANK1 and BLK in Rheumatoid Arthritis: Results From a Large Trans-Ethnic Meta-Analysis
Abstract Number: 1628

Epistatic Interaction Between Solute Carrier 2A9 Genotype and Sugar-Sweetened Beverage Consumption in the Determination of Gout Risk
Abstract Number: 2252

Epratuzumab-Treated Systemic Lupus Erythematosus Patients Report Improvements in Health-Related Quality of Life: Final Results from an Open-Label Extension Study (SL0006)
Abstract Number: 1441

Epstein Barr Virus CD40 Functional Mimic Latent Membrane Protein-1 Drives Cellular Molecular Mimicry in the Presence of Epstein Barr Virus Nuclear Antigen-1 in a Novel Murine Model of Lupus-Like Disease
Abstract Number: 1411

Equivalence of Various Language Versions of Lupus Specific Patient Reported Outcomes Measure (LupusPRO)

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].